Enzo Biochem, Inc. announced that it has entered into Securities Purchase Agreement with each of the purchasers and new investor, JGB Collateral, LLC to issue 10% Original Issue Discount Secured Convertible Debentures with an aggregate principal amount of $7,608,696 on May 19, 2023. The company will also issue warrants to purchase up to 1,000,000 shares of the Company?s common stock, par value $0.01 per share for an exercise price of $2.31 per share, the average of the 3 daily volume weighted average prices of the common stock as defined in the Purchase Agreement prior to the closing date, subject to adjustments as set forth in the warrants, for a total purchase price of $7,000,000. The Purchase Agreement contains customary representations, warranties and covenants.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | 0.00% | -2.68% | -21.58% |
1st Jan change | Capi. | |
---|---|---|
-21.58% | 55.84M | |
+29.31% | 49.18B | |
+0.92% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.27% | 26.09B | |
-22.71% | 18.71B | |
+8.11% | 13.26B | |
+32.14% | 12.32B | |
-0.68% | 11.99B |
- Stock Market
- Equities
- ENZ Stock
- News Enzo Biochem, Inc.
- Enzo Biochem, Inc. announced that it expects to receive $7.608696 million in funding from JGB Collateral, LLC